Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer

Open-label pilot of group psilocybin-assisted psychotherapy for 12 patients with cancer and comorbid depressive disorders; two cohorts of six with interim safety review between cohorts.

Intervention comprises seven group therapy sessions (three 2-hour preparatory sessions, one 8-hour psilocybin dosing session, three 2-hour integration sessions). Primary outcomes focus on feasibility and safety; secondary outcomes include depressive symptoms and existential distress.